Lantern Pharma Inc. (LTRN) Form 8-K — Aug 14, 2026
Lantern Pharma reported second quarter 2026 results and announced the formal establishment of Open Medicine AI (OMAI) as a separate wholly-owned company operating its multi-agentic AI co-scientist platform with board-approved commercial licenses, paying subscription tiers, and engineering centers in Dallas and Bengaluru. Lantern intends to raise outside capital at the OMAI level, with a longer-term objective of a separate public listing while remaining one of OMAI's largest shareholders.
Key figures
- Cash Position
- 7400000
- Shares Outstanding
- 12759146
- Cash Dec31 2025
- 10100000
- Ga Expense Q2 2025
- 1600000
- Ga Expense Q2 2026
- 1700000
- Hazard Ratio L858 R
- 0.37
- Rnd Expense Q2 2025
- 3100000
- Rnd Expense Q2 2026
- 1800000
- Clinical Benefit Rate
- 77%
- Rnd Expense Yoy Change
- -42%
- Net Loss Six Months2026
- 10400000
- Operating Loss Q2 2025
- 4700000
- Operating Loss Q2 2026
- 3500000
- Warrant Expense Q2 2026
- 3600000
- Investor Warrants Shares
- 2135923
- Lp184 TNBCTrial Patients
- 40
- Median Pfs Six Cycle L858 R
- 8.9 months
- Operating Loss Yoy Change
- -25%
- Lp184 Bladder Trial Patients
- 39
- Median Pfs Overall L858 RCohort
- 8.4 months
- Investor Warrant Exercise Price
- 2.27
- May2026 Offering Gross Proceeds
- 4400000
- Pipeline Annual Market Potential
- >$15 billion
Price after filing
Close on the filing date to close N calendar days later (from $2.65). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.